Doximity Inc. (DOCS)
NYSE NYSE Primary 
XSTU 
Doximity Stock Soars 42% Toward Best Day Ever. It's Not the Only Record.
The online medical platform reported quarterly revenue of $136.8 million and earnings of 30 cents a share, beating analysts expectations.
Doximity, Inc. (DOCS) Q2 2025 Earnings Call Transcript
Doximity, Inc. (NYSE:DOCS ) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Perry Gold - Vice President of Investor Relations Jeff Tangney - Co-Founder and CEO Anna Bryson - Chief Financial Officer Nate Gross - Co-Founder and Chief Strategy Officer Conference Call Participants Glen Santangelo - Jefferies Johnathan McCary - Raymond James Stephanie Davis - Barclays Jared Haase - William Blair Elizabeth Anderson - Evercore ISI Allen Lutz - Bank of America Dan Clark - Leerink Scott Schoenhaus - KeyBanc Scott Berg - Needham & Company Jailendra Singh - Truist Eric Percher - Nephron John Park - Morgan Stanley Operator Well, good day, everyone, and welcome to the Doximity Fiscal 2Q '25 Earnings Call. At this time, I would like to hand the call over to Mr.
Doximity (DOCS) Tops Q2 Earnings and Revenue Estimates
Doximity (DOCS) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.22 per share a year ago.
Doximity (DOCS) Outperforms Broader Market: What You Need to Know
Doximity (DOCS) closed at $41.88 in the latest trading session, marking a +1.11% move from the prior day.
Doximity (DOCS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the most recent trading session, Doximity (DOCS) closed at $41.42, indicating a -1.76% shift from the previous trading day.
3 Medical Services Stocks to Buy to Navigate Industry Challenges
The Zacks Medical - Services industry is growing on nursing care market growth and digital healthcare adoption. ELV, DOCS and HQY are set to gain the most.
Overlooked Stock: DOCS
Doximity (DOCS) is trading near its 52-week high after getting an upgrade from Barclays. George Tsilis talks about why the "LinkedIn for physicians" can be gaining investor interest.
Doximity (DOCS) Increases Despite Market Slip: Here's What You Need to Know
Doximity (DOCS) reachead $40.88 at the closing of the latest trading day, reflecting a +0.62% change compared to its last close.
SOLV vs. DOCS: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Solventum (SOLV) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?
Should You Buy This Stock After It Skyrocketed by 33%?
Doximity recently reported strong financial results. The company has solid growth opportunities.
Reconsidering Doximity Shares: Should Investors Bet On A Sustained Revenue Growth Inflection
Doximity's guidance in no way reflects the positive tea leaves management discussed during the conference call. Doximity reported better than expected Q1 results with revenues of $127 million and adjusted EBITDA of $66 million, leading to a 39% increase in share price. The company minimally increased its adjusted EBITDA forecast for FY '25, but potential for sustainable growth rates is not reflected in consensus estimates.
Doximity: The 'Facebook for Doctors' Surges After Earnings Beat
Doximity Inc. NASDAQ: DOCS is a digital professional medical networking platform that is a cross between LinkedIn and Meta Platforms Inc. NASDAQ: META Facebook. The platform enables physicians to connect with their colleagues to collaborate on patient treatments and research.
